Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy
Q Yang, OS Madueke-Laveaux, H Cun, M Wlodarczyk… - Cells, 2024 - mdpi.com
Uterine leiomyosarcoma (uLMS) is the most common subtype of uterine sarcomas. They
have a poor prognosis with high rates of recurrence and metastasis. The five-year survival …
have a poor prognosis with high rates of recurrence and metastasis. The five-year survival …
From Detection to Cure–Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer
JA Linscott, H Miyagi, PB Murthy, S Yao… - Current Oncology …, 2024 - Springer
Summary utDNA shows promise for improving all phases of bladder cancer care, paving the
way for personalized treatment strategies. Building from current research, future …
way for personalized treatment strategies. Building from current research, future …
[HTML][HTML] hTERT Epigenetics Provides New Perspectives for Diagnosis and Evidence-Based Guidance of Chemotherapy in Cancer
S Santourlidis, MJ Araúzo-Bravo, RT Brodell… - International Journal of …, 2024 - mdpi.com
Strong epigenetic pan-cancer biomarkers are required to meet several current, urgent
clinical needs and to further improve the present chemotherapeutic standard. We have …
clinical needs and to further improve the present chemotherapeutic standard. We have …
Evaluation of silica spin‑column and magnetic bead formats for rapid DNA methylation analysis in clinical and point‑of‑care settings
FT Zamuner, A Ramos‑lópez… - Biomedical …, 2024 - spandidos-publications.com
Late‑stage cancers lack effective treatment, underscoring the need for early diagnosis to
improve prognosis and decrease mortality rates. Molecular markers, such as DNA …
improve prognosis and decrease mortality rates. Molecular markers, such as DNA …
[HTML][HTML] ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable …
LR Nielsen, S Stensgaard, P Meldgaard… - Cancer Treatment and …, 2024 - Elsevier
Background Reliable biomarkers are needed to identify tumor recurrence of non-small cell
lung cancer (NSCLC) patients after chemoradiotherapy (CRT) with curative intent. This …
lung cancer (NSCLC) patients after chemoradiotherapy (CRT) with curative intent. This …